FLAG-idarubicin and allogeneic stem cell transplantation for Ph-positive ALL beyond first remission

Bone Marrow Transplantation

Volumn 22, Issue 12, 1998, Pages 1137-1143

  Deane, M ^a,b   Koh, M ^b   Foroni, L ^b   Galactowicz, G ^b   Hoffbrand, A V ^b   Lawler, M ^c   Secker Walker, L ^b   Prentice, H G ^b  

^a NORFOLK AND NORWICH HOSPITAL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c ST JAMES S HOSPITAL   (Ireland)

Author keywords

Acute lymphoblastic leukaemia; bcr abl; FLAG; Fludarabine; Peripheral blood stem cell transplantation; Philadelphia chromosome

Indexed keywords

BCR ABL PROTEIN; CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOGENETICS; DRUG TOLERABILITY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; PERIPHERAL BLOOD STEM CELL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; SCHOOL CHILD; SIBLING; TREATMENT OUTCOME;

EID: 0032439389     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701521     Document Type: Article

References (53)

1. Lestingi TM, Hooberman AL. Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematol/Oncol Clin N Am 1993; 7: 161-175.
2. Secker-Walker LM, Prentice HG, Durrant J et al. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukemia on MRC trial UKALL XA. Br J Haematol 1997; 96: 601-610.
3. Kantarjian H, Talpaz M, Dhingra K et al. Significance of the P210 vs P190 molecular abnormalities in adults with Philadelphia chromosome positive acute leukemia. Blood 1991; 78: 2411-2418.
4. Kantarjian HM, Walters RS, Keating MJ et al. Results of the vincristine, doxorubicin and dexamethasone regimen in adults with standard- and high-risk acute lymphoblastic leukemia. J Clin Oncol 1990; 8: 994-1004.
5. Barrett AJ, Horowitz MM, Ash RC et al. Bone marrow ransplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1992; 79: 3067-3070.
6. Chao NJ, Blume KG, Forman SJ, Snyder DS. Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1995; 85: 3353-3354.
7. Radich J, Gehly G, Lee A et al. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood 1997; 89: 2612-2609.
8. Casper J, Cammitta B, Ash R. Bone marrow transplantation for Philadelphia chromosome positive acute lymphocytic leukemia using alternative donors. Blood 1992; 80 (Suppl. 1): (Abstr. 65).
9. Mortimer J, Blinder MA, Schulman S et al. Relapse of acute leukemia after bone marrow transplantation: natural history and results of subsequent therapy. J Clin Oncol 1989; 7: 50-57.
10. Mrsic M, Horowitz MM, Atkinson K et al. Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant 1992; 9: 269-275.
11. Sanders JE, Buckner CD, Clift RA et al. Second bone marrow transplants in patients who relapse after allogeneic bone marrow transplantation. Bone Marrow Transplant 1988; 3: 11-19.
12. Frassoni F, Barrett AJ, Granena A et al. Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by EBMT of 117 cases. Br J Haematol 1988; 70: 317-320.
13. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
14. Drobyski WR, Keever CA, Roth MS et al. Salvage immunotherapy as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T cell dose. Blood 1993; 82: 2310-2318.
15. van Rhee F, Lin F, Cullis JO et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994; 83: 3377-3383.
16. Porter DL, Ross MS, McGarigle C et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. New Engl J Med 1994; 330: 100-106.
17. Prentice HG, Sekhar M, Popat U et al. Donor leukocyte infusion for relapsed leukemia post-BMT. Blood 1995; 86 (Suppl. 1): (Abstr. 2250).
18. Mackinnon S, Papadopoulos EB, Carabasi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261-1268.
19. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
20. Szer J, Grigg AP, Phillips GL, Sheridan WP. Donor leukocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT. Bone Marrow Transplant 1993; 11: 109-111.
21. Frassoni F, Fagiloi F, Sessarego M. The effect of donor leukocyte infusion in patients with acute leukemia following allogeneic bone marrow transplantation. Exp Hematol 1992; 20: 712 (Abstr. 30).
22. Pati AR, Godder K, Lamb L et al. Immunotherapy with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant 1995; 15: 979-981.
23. Mehta J, Powles R, Singhal S et al. Cytokine-mediated immunotherapy with or without donor leukocytes for poor-risk acute myeloid leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 16: 133-137.
24. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy: the treatment of choice for all hematological malignancies relapsing post-BMT. Blood 1996; 87: 4011-4012.
25. Ferster A, Bujan W, Mouraux T et al. Complete remission following donor lymphocyte infusion in ALL relapsing after haploidentical bone marrow transplantation. Bone Marrow Transplant 1994; 14: 331-332.
26. Bensinger WI, Weaver CH, Appelbaum FR et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655-1658.
27. Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-1672.
28. Russell JA, Brown C, Bowen T et al. Allogeneic blood cell transplants for haematological malignancy: preliminary comparison of outcomes with bone marrow transplantation. Bone Marrow Transplant 1996; 17: 703-708.
29. Gurman G, Kahveci G, Akan H et al. Allogeneic peripheral blood stem cell transplantation as a second transplant for severe aplastic anemia. Bone Marrow Transplant 1995; 15: 485-488.
30. Zecca M, Perotti C, Marradi P et al. Recombinant human G-CSF-mobilized peripheral blood stem cells for second allogeneic transplant after bone marrow graft rejection in children. Br J Haematol 1996; 92: 432-434.
31. Cobos E, Keung YK, Organ D, Park CH. Successful engraftment using allogeneic peripheral blood progenitor cells in a patient with primary bone marrow graft failure. J Hematother 1995; 4: 37-40.
32. Martinez JA, Picon I, Carral A et al. Allogeneic peripheral blood progenitor cells mobilized by G-CSF (filgrastim) for a second transplant in a patient with acute myeloid leukemia in relapse. Bone Marrow Transplant 1995; 15: 149-151.
33. Sica S, Di Mario A, Salutari P et al. Chemotherapy and recombinant human granulocyte colony-stimulating factor primed donor leukocyte infusion for treatment of relapse after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 16: 483-485.
34. Korbling M, Przepiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantages of blood over marrow allografts. Blood 1995; 85: 1659-1665.
35. Estey E, Thall P, Andreeff M et al. Use of granulocyte colony-stimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukaemia or myelodysplastic syndromes. J Clin Oncol 1994; 12: 671-678.
36. Nokes TJC, Johnson S, Grubb H et al. The use of FLAG in patients with haematological malignancies, a multi-centre experience. Br J Haematol 1996; 93 (Suppl. 1): 66 (Abstr. 254).
37. Koh MBC, Hoffbrand AV, Mehta A et al. FLAG ± Ida in the treatment of relapsed and refractory haematological malignancies. Br J Haematol 1997; 97 (Suppl. 1): 56 (Abstr. 213).
38. Visani G, Tosi P, Zinzani PL et al. FLAG (fludarabine, cytarabine, G-CSF) as a second-line therapy for acute lymphoblastic leukemia with myeloid antigen expression: in vitro and in vivo effects. Eur J Hematol 1996; 56: 308-312.
39. Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 1993; 11: 116-124.
40. Tafuri A, Andreeff M. Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 1990; 4: 826-834.
41. Estey EH, Keating MJ, McCredie KB et al. Cellular ara-CTP pharmacokinetics, response and karyotype in newly diagnosed acute myelogenous leukemia. Leukemia 1990; 4: 95-99.
42. Ross DD, Doyle LA, Yang W et al. Susceptibility of idarubicin, daunorubicin and their C-13 alcohol derivatives to transport-mediated multidrug resistance. Biochem Pharmacol 1995; 50: 1673-1683.
43. + cell determination by flow cytometry. J Hematother 1996; 5: 213-226.
44. Hughes TP, Morgan GJ, Martial P, Goldman JM. Detection of minimal residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood 1991; 77: 874-878.
45. Lawler M, McCann SR. Polymerase chain reaction-based methods for assessing chimerism following allogeneic bone marrow transplantation. In: Cotter FE (ed). Methods in Molecular Medicine, Molecular Diagnosis of Cancer. Humana Press: Totowa, NJ, 1996, pp 105-120.
46. Gehly GB, Bryant EM, Lee AM et al. Chimeric bcr-abl messenger RNA as a marker for minimal residual disease in patients transplanted for Philadelphia chromosome positive acute lymphoblastic leukemia. Blood 1991; 78: 458-465.
47. Mitterkauer G, Fodinger M, Scherrer R et al. PCR-monitoring of minimal residual leukaemia after conventional chemotherapy and bone marrow transplantation in BCR-ABL positive acute lymphoblastic leukaemia. Br J Haematol 1995; 89: 937-941.
48. Miyamura K, Tanimoto M, Morishima Y et al. Detection of Philadelphia-chromosome positive acute lymphoblastic leukemia by polymerase chain reaction: possible eradication of minimal residual disease by marrow transplantation. Blood 1992; 79: 1366-1370.
49. Antin JH. Graft-versus-leukemia: no longer an epiphenomenon. Blood 1993; 82: 2273-2277.
50. Keating MJ, O'Brien S, Robertson LE et al. New initiatives with fludarabine monophosphate in hematological malignancies. Semin Oncol 1993; 20 (Suppl. 7): 13-20.
51. Wijermans PW, Gerrits WB, Haak HL. Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Hematol 1993; 50: 292-296.
52. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
53. Kernan NA, Collins NH, Juliano L et al. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-versus-host disease. Blood 1986; 68: 770-773.